# Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

> **NCT06528769** · PHASE2 · RECRUITING · sponsor: **Gabriel Tinoco** · enrollment: 16 (estimated)

## Conditions studied

- Leiomyosarcoma
- Sarcoma

## Interventions

- **DRUG:** all-trans retinoic acid
- **DRUG:** Cemiplimab
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic resonance imaging
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT06528769
- **Lead sponsor:** Gabriel Tinoco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06528769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06528769, "Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06528769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*